Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.8M
-
Number of holders
-
157
-
Total 13F shares, excl. options
-
48.4M
-
Shares change
-
+2.4M
-
Total reported value, excl. options
-
$706M
-
Value change
-
+$37M
-
Put/Call ratio
-
4.04
-
Number of buys
-
82
-
Number of sells
-
-51
-
Price
-
$14.60
Significant Holders of Theravance Biopharma, Inc. - Common Stock (TBPH) as of Q3 2025
174 filings reported holding TBPH - Theravance Biopharma, Inc. - Common Stock as of Q3 2025.
Theravance Biopharma, Inc. - Common Stock (TBPH) has 157 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.4M shares
of 49.8M outstanding shares and own 97.18% of the company stock.
Largest 10 shareholders include Madison Avenue Partners, LP (9.51M shares), Weiss Asset Management LP (7.46M shares), Newtyn Management, LLC (4.95M shares), BlackRock, Inc. (4.07M shares), Irenic Capital Management LP (2.76M shares), VANGUARD GROUP INC (2.21M shares), Park West Asset Management LLC (1.28M shares), D. E. Shaw & Co., Inc. (1.21M shares), Oasis Management Co Ltd. (1.12M shares), and ACADIAN ASSET MANAGEMENT LLC (1.09M shares).
This table shows the top 157 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.